| Objective: To analyze the application effect of Bifidobacterium triple live powder in children with peptic ulcers. Method: 94 pediatric patients with peptic ulcers admitted from March 2021 to March 2024 were selected as the study subjects. They were randomly divided into an observation group and a control group using a random number table method, with 47 cases in each group. The observation group received a combination of Bifidobacterium triple live powder and quadruple therapy, while the control group received only quadruple therapy. The serum indicators, intestinal microbiota, Helicobacter pylori infection and clearance, and clinical efficacy of the two groups of children were observed. After 2 and 4 weeks of treatment, the levels of IFN - γ, TNF - α, and CRP in the observation group were lower than those in the control group (P<0.05), while the levels of TGF - β 1, bFGF, and VEGF were higher than those in the control group (P<0.05). The content of Clostridium perfringens was lower than that in the control group, while the content of lactic acid bacteria, bifidobacteria, and B/E values were higher than those in the control group (P<0.05); After 4 weeks of treatment, there was no significant difference in the eradication rate and clinical efficacy of Helicobacter pylori infection compared to the control group (P>0.05). Conclusion: The combined application of Bifidobacterium Triple Bioactive Powder on the basis of quadruple therapy is beneficial for inhibiting the inflammatory response of peptic ulcer wounds, increasing the level of growth factors, improving the structure of gut microbiota, and creating favorable conditions for ulcer healing, which is worthy of clinical promotion. |
